AZD 2066

AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease[1][2][3][5].

Product Specifications

CAS Number

[934282-55-0]

UNSPSC

12352005

Hazard Statement

H302, H361

Target

Calcium Channel; mGluR; Trk Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/azd-2066.html

Purity

99.8

Solubility

DMSO : 2 mg/mL (ultrasonic; warming)

Smiles

CN1C(C2=CC=NC=C2)=NN=C1O[C@@H](C3=NOC(C4=CC(Cl)=CC=C4)=C3)C

Molecular Formula

C19H16ClN5O2

Molecular Weight

381.82

Precautions

H302, H361

References & Citations

[1]Kågedal M, et al. A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-estimating occupancy in the absence of a reference region. Neuroimage. 2013 Nov 15;82:160-9.|[2]Swedberg MD, et al. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J Pharmacol Exp Ther. 2014 Aug;350 (2) :212-22. |[3]Antoniu SA. Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012) . Expert Opin Investig Drugs. 2013 Nov;22 (11) :1453-64. |[4] Jong YI, et al. Location and Cell-Type-Specific Bias of Metabotropic Glutamate Receptor, mGlu5, Negative Allosteric Modulators. ACS Chem Neurosci. 2019 Nov 20;10 (11) :4558-4570. |[5]Jiang X, et al. mGluR5 Facilitates Long-Term Synaptic Depression in a Stress-Induced Depressive Mouse Model. Can J Psychiatry. 2020 May;65 (5) :347-355.